therapeutic action: reduction of existential distress

Expanded access to psychedelic treatments: comparing American and Canadian policies

This article compares how the United States and Canada allow patients with serious health conditions like PTSD and depression to access experimental psychedelic treatments outside of clinical trials. Canada’s program has allowed over 200 patients to access psilocybin and MDMA treatments since 2022, while the US has only approved 50 patients for MDMA. The authors argue that Canada’s approach is more ethical and accessible, and suggest the US should streamline its process to help more patients who have failed conventional treatments.

Read More »

Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report

A 54-year-old man with terminal throat cancer received a single dose of LSD (100 μg) as part of psychedelic-assisted therapy delivered at his home. The treatment helped him experience relief from existential distress and feelings of peace. Six months later, he was in better psychological health, more motivated to pursue meaningful activities, and had discontinued pain medications while maintaining stability. This case demonstrates that psychedelic therapy can be safely administered at home for patients with life-threatening illnesses seeking existential relief.

Read More »
Scroll to Top